Bioeconomy

Researchers from The University of Queensland are using synthetic biology to help the world’s biggest businesses transition to net zero.

A new facility at the Australian Institute for Bioengineering and Nanotechnology is set to provide researchers with cancer vaccines tailored to individual patients.

A new parcel of federal funding will help AIBN researchers produce clinical-grade mRNA products that are safer and better quality, and will potentially cost less.

By feeding waste gases like carbon dioxide, carbon monoxide, and methane to certain bacteria, Antonia Ebert is producing bioplastics that break down naturally in the environment.

A blue-sky vision for a new, durable green polymer has won AIBN researchers global recognition at the 2024 Serendipity Collective competition in Estonia.

Heart disease is a major killer in Australia – but researchers are a beat closer to remuscularising your dodgy ticker with a lab grown solution.

AIBN researchers are using the latest sequencing technology developed by UK-based biotech Oxford Nanopore Technologies to analyse mRNA vaccines and therapies.

Hemanshi Galaiya's work in synthetic biology is just part of the wider picture of how she is changing the world.

AIBN researchers are hoping to turn the tide on ocean waste with customised seawater-degradable plastics made using 3D-printing techniques.

mRNA vaccines and therapies will be produced for clinical trials in a dedicated laboratory to be built at the Australian Institute for Bioengineering and Nanotechnology.